Purpose of Review

Multimodal pain management is the most effective way to treat postsurgical pain. However, the use of opioids for acute pain management has unfortunately been a significant contributor to the current opioid epidemic. The use of opioids should be limited and only considered a “rescue” pain medication after other modalities of pain management have been utilized.

Recent Findings

It may be difficult to curtail the use of opioids in the treatment of chronic pain; however, in the postsurgical setting, there is compelling evidence that an opioid-centric analgesic approach is not necessary for good patient outcomes and healthcare cost benefits. Opioid-related adverse effects are the leading cause of preventable harm in the hospital setting. After the realization in recent years of the many harmful effects of opioids, alternative regimens including the use of multimodal analgesia have become a standard practice in acute pain management. Exparel, a long-lasting liposomal bupivacaine local anesthetic agent, has many significant benefits in the management of postoperative pain.

Summary

Overall, the literature suggests that Exparel may be a significant component for postoperative multimodal pain control owing to its efficacy and long duration of action.

中文翻译：

---

Exparel 术后疼痛管理：全面审查

审查目的

多模式疼痛管理是治疗术后疼痛最有效的方法。然而，不幸的是，使用阿片类药物进行急性疼痛管理已成为当前阿片类药物流行的重要原因。阿片类药物的使用应该受到限制，并且只有在使用其他疼痛管理方式后才被视为一种“救援”止痛药。

最近的发现

在治疗慢性疼痛中可能难以减少阿片类药物的使用；然而，在术后环境中，有令人信服的证据表明，以阿片类药物为中心的镇痛方法对于良好的患者结果和医疗保健成本效益并不是必需的。阿片类药物相关的不良反应是医院环境中可预防伤害的主要原因。近年来，在意识到阿片类药物的许多有害影响后，包括使用多模式镇痛在内的替代方案已成为急性疼痛管理的标准做法。Exparel 是一种长效脂质体布比卡因局部麻醉剂，在管理术后疼痛方面具有许多显着益处。

概括

总体而言，文献表明 Exparel 可能是术后多模式疼痛控制的重要组成部分，因为它的功效和作用持续时间长。